Can a BiTE Immunotherapy Improve Survival in Young Patients with High-Risk Kinase-Driven B-ALL Subtypes? - Poll - MDSpire
Advertisement
Can a BiTE Immunotherapy Improve Survival in Young Patients with High-Risk Kinase-Driven B-ALL Subtypes?
Two genetic subtypes of childhood B-cell acute lymphoblastic leukemia (B-ALL) have long been associated with inferior treatment outcomes: Philadelphia chromosome-positive (Ph+) and ABL-class Philadelphia chromosome-like (Ph-like) B-ALL.